Skip to main content
Erschienen in: Journal of General Internal Medicine 5/2022

04.10.2021 | Original Research

HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management

verfasst von: Andrew S. Oseran, MD, MBA, Karthik Rao, MD, Yuchiao Chang, PhD, Wei He, MSc, Chrisanne E. Sikora, MAC, Deborah J. Wexler, MD, MSc, Daniel M. Horn, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Electronic consultation (eConsultation) offers a potential mechanism to increase access to specialty care, address knowledge gaps, and overcome therapeutic inertia in patients with type 2 diabetes (T2DM) being managed by primary care physicians (PCPs).

Objective

To develop and implement a system to provide unsolicited endocrinology eConsult for T2DM patients with HbA1c 8.5–10.5% managed by PCPs.

Design

Cluster-randomized matched cohort study with implementation evaluation.

Participants

PCPs affiliated with Massachusetts General Hospital (MGH).

Interventions

Unsolicited endocrinology eConsultation.

Main Measures

The primary clinical outcome was mean change in HbA1c at 6 months. Secondary process outcomes included referral completion rate, prescription rates of glucose-lowering medications, differences in rate of other management recommendations, change in all glucose-lowering medications, and number of face-to-face endocrinology visits.

Key Results

161 PCPs were randomly assigned to intervention (n=81) and control (n=80) arms. eConsultations were triggered on 130 patients from intervention arm PCPs. Intervention arm patients had a 0.89 (SD 1.45) decrease in HbA1c compared to 0.69 (SD 1.32) decrease in the control arm (p=0.28). There were significant differences in prescribing of glucose-lowering medications between arms. There was a 19.3% increase in patients prescribed GLP-1 RA or SGLT2i in the intervention arm compared to a 6.9% increase in control (p=0.003). There were also significant increases in prescription rates of metformin (3.1% vs −3.1%, p=0.03) and sulfonylureas (1.5% vs −6.9%, p=0.03). At 6-month follow-up, the intervention arm had 13 in-person endocrinology visits compared to 29 (p=0.012) in the control arm. PCPs were more likely to accept recommendations regarding adherence to or dose adjustment of current medications than initiation of new medications.

Conclusions

The implementation of an unsolicited endocrinology eConsult system for patients with poorly controlled T2DM is feasible. Unsolicited eConsultation was associated with increased prescribing of glucose-lowering medications without significant difference in HbA1c.

Trial Registration

Clinicaltrials.​gov registration: NCT03542084
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.CrossRef American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.CrossRef
2.
Zurück zum Zitat Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(Suppl. 12):S3–S4CrossRef Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(Suppl. 12):S3S4CrossRef
3.
Zurück zum Zitat O’Connor PJ, Bodkin NL, Fradkin J, et al. Diabetes Performance Measures: Current Status and Future Directions. Diabetes Care. 2011; 34(7): 1651-1659. O’Connor PJ, Bodkin NL, Fradkin J, et al. Diabetes Performance Measures: Current Status and Future Directions. Diabetes Care. 2011; 34(7): 1651-1659.
5.
Zurück zum Zitat Giugliano D, Maiorino MI, Bellastella G et al. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. J Am Heart Assoc. 2019 8;e012356 Giugliano D, Maiorino MI, Bellastella G et al. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. J Am Heart Assoc. 2019 8;e012356
6.
Zurück zum Zitat American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124.CrossRef American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124.CrossRef
7.
Zurück zum Zitat McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technol Ther. 2019;21(12):702-712. McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technol Ther. 2019;21(12):702-712.
8.
Zurück zum Zitat Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes Care. 2020;43(4):921-924.CrossRef Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes Care. 2020;43(4):921-924.CrossRef
10.
Zurück zum Zitat Vimalananda VG, Gupte G, Seraj SM, et al. Electronic consultations (eConsults) to improve access to specialty care: a systematic review and narrative synthesis. J Telemed Telecare. 2015;21(6):323-30. Vimalananda VG, Gupte G, Seraj SM, et al. Electronic consultations (eConsults) to improve access to specialty care: a systematic review and narrative synthesis. J Telemed Telecare. 2015;21(6):323-30.
12.
Zurück zum Zitat Wasfy JH, Rao SK, Essien UR, Richardson CA, Jeune T, Goldstein SA, Laikhter E, Chittle MD, Weil M, Wein M, Ferris TG. Initial experience with endocrinology e-consults. Endocrine. 2017; 55(2):640-642. Wasfy JH, Rao SK, Essien UR, Richardson CA, Jeune T, Goldstein SA, Laikhter E, Chittle MD, Weil M, Wein M, Ferris TG. Initial experience with endocrinology e-consults. Endocrine. 2017; 55(2):640-642.
13.
Zurück zum Zitat Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.CrossRef Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.CrossRef
14.
Zurück zum Zitat Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, Sperling LS. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145. doi: https://doi.org/10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583.CrossRefPubMedPubMedCentral Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, Sperling LS. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145. doi: https://​doi.​org/​10.​1016/​j.​jacc.​2020.​05.​037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583.CrossRefPubMedPubMedCentral
Metadaten
Titel
HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management
verfasst von
Andrew S. Oseran, MD, MBA
Karthik Rao, MD
Yuchiao Chang, PhD
Wei He, MSc
Chrisanne E. Sikora, MAC
Deborah J. Wexler, MD, MSc
Daniel M. Horn, MD
Publikationsdatum
04.10.2021
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 5/2022
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07157-x

Weitere Artikel der Ausgabe 5/2022

Journal of General Internal Medicine 5/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.